Next Article in Journal
A mini volume loading test for indication of preoperative dehydration in surgical patients
Previous Article in Journal
Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma: Analysis of recurrence-free survival
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Open AccessArticle

Use of drugs against osteoporosis in the Baltic countries during 2010–2014

1
Department of Traumatology and Orthopedics, University of Tartu, Tartu, Estonia
2
Estonian State Agency of Medicines, Tartu, Estonia
3
Clinic of Traumatology and Orthopedics, Tartu University Hospital, Tartu, Estonia
4
Department of Pathophysiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia
*
Author to whom correspondence should be addressed.
Medicina 2016, 52(5), 315-320; https://doi.org/10.1016/j.medici.2016.10.001
Received: 17 November 2015 / Revised: 20 September 2016 / Accepted: 2 October 2016 / Published: 13 October 2016
Background and objective: Osteoporosis is a major health threat nowadays. Aging of the population and changes in peoples' lifestyle result in a constant increase in the number of fractures all over the world. Our study aimed at describing the drug utilization pattern and choice of active substances of antiosteoporotic medicines in the Baltic countries.
Materials and methods: Sales data of the antiosteoporotic medicines was obtained from the internet. These are available on the website of medicines regulatory agencies. The World Health Organization (WHO) methodology of Anatomical Therapeutic Chemical (ATC) classification and defined daily dose (DDD) was used to compare the data among countries.
Results: During the study period the consumption of antiosteoporotic medicines was rather stable in all the countries. The overall choice of active substances used to treat osteoporosis is similar in all the Baltic countries but the market shares of substances were different. Estonia stands out with high use of combination product of alendronic acid and colecalci- ferol. In Latvia the highest consumption was of risedronic acid. In Lithuania the most used active substance in 2014 was ibandronic acid and second was denosumab with 0.8 daily doses per 1000 inhabitants per day (DID) and 25% of the total share.
Conclusions: The differences in consumption of drugs against osteoporosis in the Baltic countries are not very big. The consumption of antiosteoporotic drugs is not to be regarded as sufficient though. The generally low consumption of osteoporotic medicines in the Baltic countries can be attributed to the overall less than EU average wealth of the countries and less than optimal expenditure on healthcare out of the GDP.
Keywords: Osteoporosis; Bisphosphonates; Defined daily dose; Baltic countries; Drug utilization Osteoporosis; Bisphosphonates; Defined daily dose; Baltic countries; Drug utilization
MDPI and ACS Style

Laius, O.; Maasalu, K.; Kõks, S.; Märtson, A. Use of drugs against osteoporosis in the Baltic countries during 2010–2014. Medicina 2016, 52, 315-320.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Back to TopTop